Congo Health Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP
Condition:   Ebola Virus Disease, Ebola Virus Infection, Ebola Intervention:   Drug: Ansuvimab Sponsors:   Ridgeback Biotherapeutics, LP;   Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo No longer available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2021 Category: Research Source Type: clinical trials